Uncommon Immune-Mediated Disease 5) Immune-Mediated Neutropenia (๋ฉด์—ญ๋งค๊ฐœ์„ฑ ํ˜ธ์ค‘๊ตฌ๊ฐ์†Œ์ฆ)

1. Etiology

  • ํ˜ธ์ค‘๊ตฌ๊ฐ€ ๋ฉด์—ญ๋งค๊ฐœ์„ฑ์œผ๋กœ ๊ฐ์†Œํ•˜๋Š” ์งˆํ™˜.
  • idiopathic neutropenia, steroid-responsive neutropenia ๋ผ๊ณ ๋„ ํ•œ๋‹ค.
    • ๊ฐœ์™€ ๊ณ ์–‘์ด์—์„œ ๋“œ๋ฌผ๋‹ค - ํ˜ธ์ค‘๊ตฌ๊ฐ์†Œ์ค‘ ์ผ€์ด์Šค ์ค‘ 0.4% ์ •๋„.
    • ๋ฉด์—ญ๋งค๊ฐœ ์งˆํ™˜์˜ ๋‹ค๋ฅธ ์›์ธ์„ ๋ฐฐ์ œํ•˜๊ณ , ์Šคํ…Œ๋กœ์ด๋“œ์— ๋ฐ˜์‘์„ฑ์ด ์ข‹์œผ๋ฉด ์ด ์งˆํ™˜์œผ๋กœ ์ง„๋‹จํ•  ์ˆ˜ ์žˆ๋‹ค.
  • ์ง„๋‹จ ๋ฐฉ๋ฒ• 2๊ฐ€์ง€ (but ๋”ฑํžˆ ํ•„๋“œ์—์„œ ์ž˜ ์ด์šฉ๋˜์ง€ ์•Š์Œ)
    • Flow cytometry๋กœ ํ˜ˆ์ฒญ ๊ฒ€์‚ฌํ•˜์—ฌ ํ˜ธ์ค‘๊ตฌ์— ํ•ญ์ฒด ์œ ๋ฌด ํ™•์ธ (Antineutrophil IgG antibodies)
    • ๊ณจ์ˆ˜์— ์กด์žฌํ•˜๋Š” myeloid cell์— ๋Œ€ํ•œ ํ•ญ์ฒด์™€ ๋ณด์ฒด ๊ฒ€์‚ฌ
  • ๊ฐœ์—์„œ ๋ณด๊ณ ๋œ ๋Œ€๋ถ€๋ถ„์€ primary case. ๊ณ ์–‘์ด์—์„œ๋Š” ๋ณด๊ณ ๋œ ๊ฒŒ 1์ผ€์ด์Šคโ€ฆ

2. Clinical Features & Diagnosis (๋…ผ๋ฌธ)

IMN ์˜์‹ฌ ์ผ€์ด์Šค 35๋งˆ๋ฆฌ์— ๋Œ€ํ•œ ํ›„ํ–ฅ์  ์—ฐ๊ตฌ - ํ‘œ๋ณธ์ด ๋งŽ์ง€ ์•Š์•„์„œ ์‹ ๋ขฐ๋„๋Š”..

Clinical signs
  • ๋‹ค์–‘ํ•œ ํ’ˆ์ข…์—์„œ ๋‚˜ํƒ€๋‚จ.
  • ์ฃผ๋กœ ๋น„ํŠน์ด์ ์ธ ์ฆ์ƒ์ด ๋‚˜ํƒ€๋‚จ.
  • Spayed female์—์„œ ์กฐ๊ธˆ ๋” ๋งŽ์ด ๋‚˜ํƒ€๋‚จ. (22/35)
  • ์ž„์ƒ ์ฆ์ƒ์€ ์ฃผ๋กœ ๋น„ํŠน์ด์ ์ธ ์ „์‹  ์ฆ์ƒ - fever, lameness, anorexia, lethargy ๋“ฑ
  • 3์ผ~180์ผ ๋™์•ˆ ์ฆ์ƒ์ด ๋‚˜ํƒ€๋‚จ.
  • ์ฃผ๋กœ ์–ด๋ฆฐ ๋‚˜์ด์—์„œ ๋‚˜ํƒ€๋‚˜๋ฉฐ, ๋…ธ๋ น์—์„œ๋„ ๋‚˜ํƒ€๋‚จ. ์ค‘๊ฐ„๊ฐ’์€ 5์‚ด.
1) CBC์—์„œ์˜ ๋น„์ •์ƒ ์†Œ๊ฒฌ
  • ๋งค์šฐ๋งค์šฐ ์‹ฌ๊ฐํ•œ neutropenia (๋ณดํ†ต 3,000~11,000 ์ •๋„๊ฐ€ ์ •์ƒ ๋ฒ”์œ„์ธ๋ฐ, 110 cells/ฮผL ์ •๋„)
    • ์ด ์ •๋„๋ฉด ํ•ญ์•”์น˜๋ฃŒํ•  ๋•Œ๋ณด๋‹ค ์œ„ํ—˜ํ•œ ์ˆ˜์น˜.. ํ˜ธ์ค‘๊ตฌ๊ฐ€ <1,500์ด๋ฉด ํ•ญ์•”์น˜๋ฃŒ๋„ ์ง„ํ–‰X
  • Thrombocytopenia๋„ ํ•จ๊ป˜ ๋‚˜ํƒ€๋‚จ
    • 1/4์—์„œ๋Š” IMN + ITP (neutropenia + thrombocytopenia) ํ•จ๊ป˜ ๋‚˜ํƒ€๋‚จ.
  • Mild anemia๊ฐ€ ๋‚˜ํƒ€๋‚˜๊ธฐ๋„ ํ•จ.
2) Serum biochemistry panel
  • Hyperglobulinemia (๊ณ ๊ธ€๋กœ๋ถˆ๋ฆฐํ˜ˆ์ฆ)
  • Alkaline phosphatase activity ์ฆ๊ฐ€
3) Further evaluation
  • Secondary ๊ฐ๋ณ„ ์œ„ํ•œ ์ถ”๊ฐ€ ๊ฒ€์‚ฌ์—์„œ ๋‹ค๋ฅธ ์›์ธ X
4) Bone marrow ๊ฒ€์‚ฌ
  • Myeloid hyperplasia > Myeloid hypoplasia

๋‹ค๋ฅธ ํ˜ธ์ค‘๊ตฌ๊ฐ์†Œ์ฆ์˜ ์›์ธ์„ ๋ฐฐ์ œํ•˜์—ฌ ์ง„๋‹จ.

3. Clinical diagnosis & Treatment

  • ์ž„์ƒ์ ์œผ๋กœ ์ง„๋‹จํ•  ๋•Œ๋Š” ๋‹ค๋ฅธ neutropenia์˜ ์›์ธ์„ ๋ฐฐ์ œํ•˜์—ฌ ์ด๋ฃจ์–ด์ง„๋‹ค.
  • Flow cytometry๋กœ ํ˜ธ์ค‘๊ตฌ์— ๋Œ€ํ•œ ํ•ญ์ฒด(antineutrophil antibodies)๊ฐ€ ๋ฐœ๊ฒฌ๋  ์ˆ˜ ์žˆ์œผ๋‚˜, ํ•œ๊ตญ์—์„œ๋Š” ๊ฒ€์‚ฌ ๋ถˆ๊ฐ€..
  • Presumptive diagnosis(์ถ”์ •์ƒ ์ง„๋‹จ) : ์Šคํ…Œ๋กœ์ด๋“œ(gluticorticoid) ์น˜๋ฃŒ์— ์ข‹์€ ๋ฐ˜์‘์„ ๋ณด์ด๋ฉด ์ž ์ • ์ง„๋‹จ๋  ์ˆ˜ ์žˆ๋‹ค. (2-4mg/kg/day PO)
  • ์ดˆ๊ธฐ์— PDS ๋ฐ˜์‘ ์—†๊ฑฐ๋‚˜, PDS tapering ์ค‘ ์žฌ๋ฐœํ–ˆ์„ ๋•Œ โ‡’ Azathioprine, cyclosporine์„ ์ถ”๊ฐ€ํ•œ๋‹ค.
  • ์ ์ง„์ ์œผ๋กœ ์Šคํ…Œ๋กœ์ด๋“œ ์‚ฌ์šฉ ์ค‘์ง€.
  • ์žฅ๊ธฐ๊ฐ„ ๋ฉด์—ญ ์–ต์ œ ์น˜๋ฃŒ๋ฅผ ์š”ํ•˜๊ธฐ๋„ ํ•œ๋‹ค.
  • ํ˜ธ์ค‘๊ตฌ ๊ฐ์†Œ โ‡’ ๊ฐ์—ผ์— ์ทจ์•ฝํ•ด์งˆ ์ˆ˜ ์žˆ์œผ๋ฏ€๋กœ, ๊ฐ์—ผ์— ๋Œ€ํ•œ ๋ชจ๋‹ˆํ„ฐ๋ง์ด ์ค‘์š”ํ•˜๋‹ค.